Monthly Income With Dividends In March 2024

Welcome to a new report of my Dividend Diary on the TEV Blog. Here, I report the development of a cash flow-oriented investment approach that focuses on generating a passive income through dividends. Against this background, the goal is not to outperform the market but to put food on the table through a regular income via dividends.


With the Dividend Diary, I document how a cash-flow investment approach can be part of well-balanced wealth management. To keep things simple, I have built three pillars:

  • Active income.
  • Passive income.
  • Conversion.

Dividends fall into the last two categories. They are passive because they provide a cash flow without me going to work. Additionally, they are an essential pillar for conversion since they can be reinvested to generate even more income in the future. That is the Theory. Now let’s get down to practice.


My monthly income with dividends in March:

This month, my cash-flow approach generated the following income through dividends:

  • Pfizer (42.16 EUR)
  • Johnson & Johnson (18.62 EUR)
  • USA Financials ETF (69.50 EUR)
  • IBM (33.67 EUR)
  • Snap-on (38.34 EUR)
  • 3M (31.50 EUR)
  • Realty Income (19.72 EUR)
  • Main Street Capital (19.92 EUR)
  • Cboe Global Markets (4.39 EUR)
  • Stanley Black & Decker (11.39 EUR)
  • Qualcomm (31.98 EUR)
  • Novo Nordisk (27.57 EUR)
  • Unilever (47.81 EUR)
  • Meta Platforms (1.96 EUR)
  • Imperial Brands (15.07 EUR)
  • FTSE Japan USD ETF (5.12 EUR)
  • Booking Holdings (1.81 EUR)
  • Emerging Markets ETF (5.67 EUR)
  • Broadcom (28.71 EUR)
  • Extra Space Storage (14.83 EUR).

The total monthly income with dividends in March (after taxes) was: € 469.74 / appr. $ 506

Dividend income report check

Compared to last year, the performance was great (+ 46 percent YoY). Overall, the development looks like this:

TEV Blog Dividend Monthly Income Report dividends per month are coming in with a fluffy pink in March
TEV Blog Dividend Monthly Income Report: dividends per month are coming in with a fluffy pink in March

Stocks I sold in March

Due to their lack of business performance and dividend increases, I sold all of my shares in Henkel. This is part of my current strategy adjustment, where I am trying to streamline my portfolio a bit. You can read more about the reasons behind it in this article about my investment mistakes and the learnings I gained. I have allocated the freed-up capital to the current savings plans listed below.

Stock purchases in March

I bought more shares of great companies via my already existing automatic investment plans:

  • AbbVie
  • Amdocs 
  • Alexandria Real Estate REIT
  • Automatic Data Processing
  • Bristol-Myers Squibb
  • Cboe Global Markets
  • CVS Health
  • Diageo
  • Extra Space Storage
  • Emerging Markets ETF
  • Generals Mills
  • Japan ETF 
  • Kontron
  • Mensch & Maschine
  • PepsiCo.
  • Realty Income
  • Snap-on 
  • Qualcomm
  • Williams-Sonoma
  • Pfizer (paused in February)
  • Cisco Systems (paused in January)
  • General Dynamics (paused in January)
  • IBM (paused in January)
  • Henkel (paused in November)
  • Mayr-Melnhof Karton (paused in December)
  • Siemens (paused in December)
  • Stemmer Imaging (paused in January)
  • USU Software (paused in January)
  • Unilever  (paused in November)
  • Valmet (paused in December).
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Share your thoughts by writing a comment! :)x
()
x